Evidence map›Paper›PMID 27796820›Full record

Trial reportClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer.

A J Conde-Moreno, G Herrando-Parreño, R Muelas-Soria, J Ferrer-Rebolleda, R Broseta-Torres, M P Cozar-Santiago, F García-Piñón, C Ferrer-Albiach

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02858128 (WHOLE-BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02858128 completednot on this map

WHOLE-BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING (WB-DW-MRI) VS CHOLINE-POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY (CHOLINE- PET/CT) for Selecting Treatments in Recurrent Prostate Cancer

TypeobservationalSponsorHospital Provincial de CastellonRan2014 to 2015Enrolled46ConditionsProstate CancerArmsIMAGING STUDY
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Oligometastases in prostate cancer: Ablative treatment.World journal of clinical oncology · 2019
    Review
  5. Whole Body MRI and oncology: recent major advances.The British journal of radiology · 2018
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

A J Conde-MorenoRadiation Oncology Department, Consorcio Hospitalario Provincial de Castellón, Castellón, Spain. antoniojconde@gmail.com.ORCID http://orcid.org/0000-0003-1024-0924
G Herrando-ParreñoRadiation Oncology Department, Consorcio Hospitalario Provincial de Castellón, Castellón, Spain.
R Muelas-SoriaRadiation Oncology Department, Consorcio Hospitalario Provincial de Castellón, Castellón, Spain.
J Ferrer-RebolledaNuclear Medicine Department, Eresa Hospital General de Valencia, Valencia, Spain.
R Broseta-TorresMRI Department, Eresa-Hospital General de Castellón, Valencia, Spain.
M P Cozar-SantiagoNuclear Medicine Department, Eresa Hospital General de Valencia, Valencia, Spain.
F García-PiñónBiostatistics Department, Fundación Hospital Provincial de Castellón, Consorcio Hospitalario Provincial de Castellón, Castellón, Spain.
C Ferrer-AlbiachRadiation Oncology Department, Consorcio Hospitalario Provincial de Castellón, Castellón, Spain.
Consorcio Hospitalario Provincial de Castellón · ESHospital General Universitari de Castelló · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the effectiveness of whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) in detecting metastases by comparing the results with those from choline-positron emission tomography-computed tomography (choline-PET/CT) in patients with biochemical relapse after primary treatment, and no metastases in bone scintigraphy, CT and/or pelvic MRI, or metastatic/oligometastatic prostate cancer (PCa). Patients with this disease profile who could benefit from treatment with stereotactic body radiation therapy (SBRT) were selected and their responses to these techniques were rated. MATERIALS AND

methodsThis was a prospective, controlled, unicentric study, involving 46 consecutive patients from our centre who presented biochemical relapse after adjuvant, salvage or radical treatment with external beam radiotherapy, or brachytherapy. After initial tests (bone scintigraphy, CT, pelvic MRI), 35 patients with oligometastases or without them were selected. 11 patients with multiple metastases were excluded from the study. WB-DW-MRI and choline-PET/CT was then performed on each patient within 1 week. The results were interpreted by specialists in nuclear medicine and MRI. If they were candidates for treatment with ablative SBRT (SABR), they were then evaluated every three months with both tests.

resultsCholine-PET/CT detected lesions in 16 patients that were not observable using WB-DW-MRI. The results were consistent in seven patients and in three cases, a lesion was observed using WB-DW-MRI that was not detected with choline-PET/CT. The Kappa value obtained was 0.133 (p = 0.089); the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of WB-DW-MRI were estimated at 44.93, 64.29, 86.11, and 19.15%, respectively. For choline-PET/CT patients, the sensitivity, specificity, PPV, and NPV were 97.10, 58.33, 93.06, and 77.78%, respectively.

conclusionsCholine-PET/CT has a high global sensitivity while WB-DW-MRI has a high specificity, and so they are complementary techniques. Future studies with more enrolled patients and a longer follow-up period will be required to confirm these data. The initial data show that the best technique for evaluating response after SBRT is choline-PET/CT. Trial registration number NCT02858128.

Indexed as

AgedAged, 80 and overCholineDiffusion Magnetic Resonance ImagingHumansMaleMiddle AgedNeoplasm Recurrence, LocalPilot ProjectsPositron Emission Tomography Computed TomographyProspective StudiesProstatic NeoplasmsSensitivity and SpecificityCholineCholine-PET/CTOligometastasesProstate cancerWB-DW-MRI

Identifiers

PMID27796820
OpenAlexW2544697598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.